Off-Label Practices Plague Circulatory System Device Randomized Trials
This article was originally published in The Gray Sheet
Executive Summary
Off-label use of biliary stents is hindering superficial femoral artery (SFA) device development, CDRH Division of Cardiovascular Devices Director Bram Zuckerman told participants at CRT 2004 in Washington, D.C
You may also be interested in...
Current, Former FDA Circ Panel Chairs Stress Need For Data On PFO Devices
The medical community should curtail off-label use of patent foraman ovale closure devices and support ongoing randomized trials, according to a July 20 Journal of the American Medical Association column
Current, Former FDA Circ Panel Chairs Stress Need For Data On PFO Devices
The medical community should curtail off-label use of patent foraman ovale closure devices and support ongoing randomized trials, according to a July 20 Journal of the American Medical Association column
FDA Expects Wide Range Of Peripheral Drug-Eluting Stent Applications
FDA may consider granting a broad indication to leg stents based on data from the "worst" part of the leg vasculature, according to CDRH Peripheral Vascular Devices Branch Chief David Buckles, PhD